News GSK confirms plan to buy cancer firm IDRx for $1bn GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.
News Biogen offers to buy out wilting Sage for $442 million Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.
News Is GSK prepping a $1bn takeover bid for IDRx? GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.
News Galapagos unveils plan to split, hiving off its drugs unit Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.
Market Access The biopharma outlook for 2025: Opportunities and challenges With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how cap
News London-listed Poolbeg discussing Hookipa merger The UK's Poolbeg Pharma has disclosed that it is in talks over a possible takeover by Hookipa, an Austrian biotech that is listed on the Nasdaq.
News Chai raises $130m for AI drug discovery platform AI specialist Chai Discovery has said it is sitting on a valuation of around $1.3 billion, after raising $130 million in a Series B financing.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
